Fig. 3: Forest plot of mean predicted survival probability and 95% CI for healthy adults aged >50 years, PLWH (aged 18-50 years), and children (aged 1-17 years); PPI analysis set. | npj Vaccines

Fig. 3: Forest plot of mean predicted survival probability and 95% CI for healthy adults aged >50 years, PLWH (aged 18-50 years), and children (aged 1-17 years); PPI analysis set.

From: Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Fig. 3

This analysis was based on the pooled data of participants vaccinated with Ad26.ZEBOV, MVA-BN-Filo in a 56-day interval in five clinical studies (EBL2001, EBL2002, EBL3001, EBL3002, and EBL3003) using a logistic regression model based on data from NHPs vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval. CI confidence interval, EU enzyme-linked immunosorbent assay units, NHP non-human primate, PLWH people living with human immunodeficiency virus, PPI per-protocol immunogenicity. *PLWH were on a stable antiretroviral therapy regimen, had a CD4 + cell count >350 cells/μL, and were considered to be in otherwise reasonably good medical condition.

Back to article page